```html

Toxic Epidermal Necrolysis (TEN) – A Comprehensive Medical Guide

Overview

Toxic epidermal necrolysis (TEN) is a rare, life‑threatening skin disorder characterized by widespread necrosis (death) of the epidermis, leading to large areas of skin sloughing that resemble severe burns. TEN is considered the most severe end of a disease spectrum that includes Stevens‑Johnson syndrome (SJS) and the overlapping SJS/TEN category.

• Incidence: Approximately 0.4–1.9 cases per million person‑years worldwide, with higher rates in North America and Europe.<sup>[1] CDC, 2023</sup>
• Mortality: Reported case‑fatality rates range from 25–35 % for TEN, compared with 5–10 % for SJS.<sup>[2] WHO, 2022</sup>
• Typical age group: Most cases occur in adults 40–60 years old, but TEN can affect children and the elderly.
• Gender: Slight female predominance (≈55 % of cases).

The condition is triggered primarily by medications, but infections and, rarely, vaccinations can also precipitate it. Because the skin barrier is lost, patients are at high risk for infection, fluid loss, and multisystem organ failure, making early recognition and treatment critical.

Symptoms

Symptoms usually develop 1–3 weeks after exposure to the offending agent. They progress rapidly, and the entire clinical picture can evolve within 48–72 hours.

• Prodromal phase (fever, malaise): Low‑grade fever, chills, sore throat, cough, and malaise resembling a flu‑like illness.
• Skin pain: Burning or tenderness before any visible rash.
• Rash:
  • Macules → erythematous patches that become dusky.
  • Blisters (bullae) that quickly rupture, leaving raw, denuded areas.
  • Positive Nikolsky sign – gentle lateral pressure causes the epidermis to separate.
  • Skin detachment >30 % of body surface area (BSA) defines TEN; 10–30 % is SJS/TEN overlap.
• Mucosal involvement (≥2 sites required for SJS/TEN diagnosis): painful erosions of the mouth, eyes, genitalia, and respiratory tract.
• Eye complications: Conjunctivitis, photophobia, corneal ulceration, which can lead to blindness if untreated.
• Respiratory symptoms: Cough, dyspnea, or airway ulcerations that may cause stridor.
• Gastrointestinal: Oral ulcerations and difficulty swallowing; rare involvement of the esophagus.
• Systemic signs: Hypotension, tachycardia, and signs of sepsis from bacterial translocation.

Causes and Risk Factors

Primary Triggers

• Medications (90 % of cases):
  • High‑risk: Antiepileptics (carbamazepine, lamotrigine, phenytoin), sulfonamide antibiotics, allopurinol, non‑steroidal anti‑inflammatory drugs (NSAIDs, especially oxicam derivatives), and some antiretrovirals.
  • Moderate risk: Penicillins, cephalosporins, quinolones, and certain antihypertensives.
• Infections: Mycoplasma pneumoniae, herpes simplex virus, cytomegalovirus, and rare bacterial agents have been implicated.
• Vaccines: Extremely rare cases reported after influenza and COVID‑19 vaccines; the benefit of immunization far outweighs risk.

Risk Factors

• Genetic predisposition – HLA‑B*1502 in Asian populations increases carbamazepine‑associated TEN.<sup>[3] NIH, 2022</sup>
• Previous SJS/TEN episode – recurrence risk up to 10 %.
• Immunocompromised state – HIV infection, organ transplantation, or chronic corticosteroid use.
• Older age – reduced hepatic metabolism leads to higher drug levels.
• Polypharmacy – the more drugs taken, the greater the exposure risk.

Diagnosis

Diagnosis is clinical, supported by laboratory and histopathologic data. Early involvement of a dermatologist and a burn‑center or intensive care unit (ICU) is essential.

Clinical Assessment

• Detailed drug history covering the previous 8 weeks.
• Calculation of % BSA involved (rule of nines). TEN is defined when >30 % is detached.
• Assessment of mucosal sites (oral, ocular, genital, respiratory).

Laboratory Tests

• Complete blood count – may show leukocytosis or eosinophilia.
• Electrolytes, renal and liver function – monitor for organ involvement.
• Inflammatory markers (CRP, ESR).
• Blood cultures – to detect secondary sepsis.
• Serology for infectious triggers when suspected.

Skin Biopsy

Performed in 70–90 % of cases to confirm diagnosis:

• Full‑thickness epidermal necrosis.
• Sparse lymphocytic infiltrate at the dermal‑epidermal junction.
• Absence of vasculitis distinguishes it from other blistering disorders.

Scoring Systems

• SCORTEN – Seven‑item severity score predictive of mortality (age > 40, malignancy, >10 % BSA detachment, serum urea >10 mmol/L, glucose >14 mmol/L, bicarbonate <20 mmol/L, heart rate >120 bpm).<sup>[4] Cleveland Clinic, 2021</sup>

Treatment Options

Because TEN is a medical emergency, treatment begins in an ICU or specialized burn unit with multidisciplinary input (dermatology, ophthalmology, infectious disease, nutrition, and wound‑care nursing).

Immediate Measures

• Discontinue the suspected drug(s) immediately. Even if the trigger is unclear, stop all non‑essential medications.
• Supportive care modeled on burn management:
  • Fluid resuscitation using the Parkland formula (4 mL × body weight kg × % BSA) with lactated Ringer’s solution.
  • Thermoregulation – maintain a neutral environment.
  • Pain control – IV opioids (e.g., fentanyl, morphine) titrated to effect.
• Strict aseptic technique; isolation to prevent infection.

Pharmacologic Therapies

• Corticosteroids: High‑dose IV methylprednisolone (1–2 mg/kg/day) for up to 3 days may be used early; evidence is mixed, and risk of infection is a concern.
• Intravenous Immunoglobulin (IVIG): 2 g/kg divided over 3–5 days. Meta‑analyses suggest modest benefit when given <48 h after onset.<sup>[5] Mayo Clinic, 2022</sup>
• Cyclophosphamide or Cyclosporine: Cyclosporine 3–5 mg/kg/day has shown mortality reduction in several cohort studies.
• TNF‑α inhibitors (e.g., etanercept): Emerging data (small RCTs) indicate faster skin healing and lower SCORTEN scores.
• Antibiotics only for documented infections – prophylactic antibiotics are NOT recommended.

Wound Care

• Non‑adhesive, semipermeable dressings (e.g., Mepitel®) to protect raw surfaces.
• Debridement is performed conservatively; aggressive surgical removal is avoided.
• Topical antimicrobial agents (e.g., silver sulfadiazine) may be used unless sulfa allergy exists.

Ophthalmologic Management

• Frequent lubrication with preservative‑free artificial tears.
• Topical corticosteroids (prednisolone acetate) for conjunctival inflammation.
• Urgent referral for amniotic membrane transplantation if corneal involvement is severe.

Rehabilitation & Nutrition

• High‑protein, high‑calorie enteral nutrition (30–35 kcal/kg/day, 1.5 g protein/kg/day).
• Physical therapy to prevent contractures and maintain joint range of motion.
• Psychological support – the disease can be traumatic.

Living with Toxic Epidermal Necrolysis (TEN)

Survivors often face long‑term sequelae. A structured follow‑up plan improves outcomes.

Skin Care

• Gentle cleansing with mild, fragrance‑free soaps.
• Moisturize twice daily with emollients containing ceramides.
• Avoid sun exposure; use broad‑spectrum SPF 30+ sunscreen.

Ocular Health

• Continue lubricants and follow up with an ophthalmologist every 3–6 months for the first year.
• Report any new eye pain, redness, or visual changes promptly.

Genital and Oral Care

• Use saline rinses and non‑alcoholic mouthwashes.
• Apply topical barrier creams (e.g., zinc oxide) to protect perineal skin.

Psychosocial Support

• Consider counseling or support groups for post‑traumatic stress.
• Educate family members about the risk of medication reactions.

Medication Safety

• Maintain an up‑to‑date “drug allergy” bracelet and a written list of offending agents.
• Ask all healthcare providers to verify drug history before prescribing.
• Electronic health record alerts for known high‑risk HLA alleles when applicable.

Prevention

• Pharmacogenomic screening: Test for HLA‑B*1502 in people of Asian ancestry before initiating carbamazepine or oxcarbazepine.<sup>[3] NIH, 2022</sup>
• Prescribe the lowest effective dose of high‑risk drugs and limit duration.
• Educate patients about early signs (fever, flu‑like symptoms, painful rash) and advise immediate discontinuation of new drugs.
• Avoid unnecessary polypharmacy; review medication lists annually.
• In hospitals, implement “drug‑trigger alerts” in computerized order entry systems.

Complications

If not promptly treated, TEN can lead to severe, potentially fatal complications:

• Sepsis: Bacterial invasion through denuded skin is the leading cause of death.
• Fluid‑electrolyte imbalance: Similar to burn patients; can cause renal failure.
• Acute respiratory distress syndrome (ARDS): Due to pulmonary involvement or sepsis.
• Multi‑organ failure: Liver, heart, and kidney dysfunction.
• Chronic ocular sequelae: Dry eye, symblepharon, corneal scarring, even blindness.
• Scarring and contractures: May limit mobility and require reconstructive surgery.
• Psychological impact: Depression, anxiety, and post‑traumatic stress disorder (PTSD).

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Stevens‑Johnson Syndrome and Toxic Epidermal Necrolysis. 2023. cdc.gov
2. World Health Organization. Adverse Drug Reactions: Global Estimates. 2022.
3. National Institutes of Health. Pharmacogenomics of Carbamazepine‑Induced TEN. 2022. PubMed
4. Cleveland Clinic. SCORTEN – Severity of Illness Score for TEN. 2021.
5. Mayo Clinic Proceedings. IVIG in the Management of SJS/TEN: A Systematic Review. 2022.

```